Effects of a low-dose oral estrogen only treatment on bone mineral density and quantitative ultrasonometry in postmenopausal women

References

• DVO. DVO Guideline 2009 for Prevention, Diagnosis and Therapy of Osteoporosis in Adults. Heft 11 A.D.;1(1-104):55–74.
   Google Scholar
• Pfeilschifter J, Pientka L, Scheidt-Nave Ch. [Osteoporosis in Germany, 2003 – a stock taking]. MMW Fortschr Med 2003;145:42–43.
   PubMedGoogle Scholar
• Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9–16.
   PubMed Web of Science ®Google Scholar
• Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891–2897.
   PubMed Web of Science ®Google Scholar
• Richman S, Edusa V, Fadiel A, Naftolin F. Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy. Menopause 2006;13:148–155.
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004;291:1701–1712.
   PubMed Web of Science ®Google Scholar
• Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 2003;290:1729–1738.
   PubMed Web of Science ®Google Scholar
• Jackson RD, Wactawski-Wende J, LaCroix AZ, Pettinger M, Yood RA, Watts NB, Robbins JA, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women’s health initiative randomized trial. J Bone Miner Res 2006;21:817–828.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Al-Azzawi F. Prevention of postmenopausal osteoporosis and associated fractures: Clinical evaluation of the choice between estrogen and bisphosphonates. Gynecol Endocrinol 2008;24:601–609.
   PubMed Web of Science ®Google Scholar
• Khosla S, Melton LJ 3rd, Riggs BL. The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res 2011;26:441–451.
   PubMed Web of Science ®Google Scholar
• Menostar: a low-dose estrogen patch for osteoporosis. Obstet Gynecol 2005;105:432–433.
   Google Scholar
• Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;59:2–6.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;16:372–379.
   PubMed Web of Science ®Google Scholar
• Hadji P. [Possibilities and limitations of quantitative ultrasonometry in clinical practise]. Dtsch Med Wochenschr 2003;128:951–953.
   Google Scholar
• Hadji P. [Possibilities and limitations of quantitative ultrasonometry in clinical practise]. Dtsch Med Wochenschr 2003;128:951–953.
   Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;16:372–379.
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Neusy S, Barudy J, Fellemens C, Jahjah L.. [Estrogen replacement therapy: for whom, why and how?] Rev Med Brux 2002;23:A382–A389.
   Google Scholar
• Genant HK, Lucas J, Weiss S, Akin M, Emkey R, McNaney-Flint H, Downs R, et al. Low-dose esterified estrogen therapy: effects on bone, plasma estradiol concentrations, endometrium, and lipid levels. Estratab/Osteoporosis Study Group. Arch Intern Med 1997;157:2609–2615.
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;59:2–6.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;16:372–379.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA 2002;287:2668–2676.
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int 2005;16:372–379.
   PubMed Web of Science ®Google Scholar
• Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25–54.
   PubMed Web of Science ®Google Scholar
• Gambacciani M, de Aloysio D, Elia D, van der Mooren MJ, Hadji P, Wüster C. Quantitative ultrasound (QUS) of bone in the management of postmenopausal women. Maturitas 2004;47:139–149.
   PubMed Web of Science ®Google Scholar
• Heikkinen J. Hormone therapy: maximizing the benefits. Gynecol Endocrinol 2006;22:160–162.
   PubMed Web of Science ®Google Scholar